New CervoMed Board Member Hollingsworth Granted $52,812 in Stock Options

Rhea-AI Filing Summary

CervoMed Director Jane H. Hollingsworth received a stock option grant following her election to the company's board of directors at the 2025 Annual Meeting of Stockholders. The transaction details include:

• Grant of options to purchase 8,100 shares of common stock
• Exercise price set at $6.52 per share
• Options granted on June 23, 2025 with expiration on June 23, 2035
• Vesting schedule: Monthly over one year in equal 1/12th increments
• Vesting begins June 30, 2025, subject to continued service

The stock options were granted under the company's 2025 Equity Incentive Plan in accordance with their non-employee director compensation policy. The Form 4 was filed by William R. Elder as attorney-in-fact for Hollingsworth.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hollingsworth Jane H

(Last) (First) (Middle)

20 PARK PLAZA, SUITE 424

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.52	06/23/2025		A		8,100		(1)	06/23/2035	Common Stock	8,100	$0	8,100	D

Explanation of Responses:

1. On June 23, 2025, in connection with the Reporting Person's election to the Issuer's board of directors at its 2025 Annual Meeting of Stockholders, the Reporting Person was granted an option to purchase 8,100 shares of the Issuer's common stock under the Issuer's 2025 Equity Incentive Plan in accordance with the terms of the Issuer's non-employee director compensation policy. The shares of common stock underlying the award will vest on a monthly basis over a one-year period in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2025, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ William R. Elder, attorney-in-fact for the Reporting Person	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did CRVO director Jane Hollingsworth receive in June 2025?

Jane Hollingsworth received stock options to purchase 8,100 shares of CRVO common stock at an exercise price of $6.52 per share on June 23, 2025. The options were granted under the company's 2025 Equity Incentive Plan following her election to the board of directors.

When do Jane Hollingsworth's CRVO stock options vest?

The stock options vest monthly over a one-year period in equal 1/12th increments on the last day of each month, beginning June 30, 2025. Vesting is subject to Hollingsworth's continued service as a director through each applicable vesting date.

What is the expiration date for CRVO director Hollingsworth's stock options?

The stock options granted to Jane Hollingsworth expire on June 23, 2035, which is 10 years from the grant date of June 23, 2025.

How many CRVO shares does Jane Hollingsworth own directly?

Based on the Form 4 filing, Jane Hollingsworth holds 8,100 stock options (derivative securities) directly. The filing does not show any direct ownership of non-derivative CRVO common stock.

Why did CRVO grant stock options to Jane Hollingsworth in June 2025?

The stock options were granted to Jane Hollingsworth in connection with her election to CervoMed's board of directors at the 2025 Annual Meeting of Stockholders, in accordance with the company's non-employee director compensation policy.